The US Levofloxacin Hemihydrate market started to pick up steam in the first half of December 2025, capitalizing on the price increase seen in November. After essentially flat lining in the previous month, early December saw prices start to tick up as buyers came back into the market to stock up ahead of the year-end rush. With hospitals and generic drug manufacturers finally getting a clearer view of the demand picture, and expectations of higher healthcare-related needs on the horizon, the market started to move upwards. On the supply side, import availability was steady but not exactly flooding the market, which meant sellers could maintain some firmness in their pricing. Meanwhile, despite no major issues with logistics and costs, buyers were getting a bit cautious about the limited availability of stock and the cautious way they were holding onto their inventory. As a result, supply assurance was starting to take priority over trying to negotiate the price, which helped to lift market sentiment a bit. Looking down the track, the experts in the industry are expecting things to keep getting tighter still, with the end of year stock replenishment and ongoing medical needs probably pushing buyers into a frenzied purchasing mode, and that could very well squeeze supply conditions even further.
